Sign In
Buy ONCT
$0.527
+0 (+0%)
At Close: Feb 28, 2025
Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma
12:00am, Tuesday, 30'th Jun 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today
ONCTERNAL THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) | MarketScreener
08:55pm, Monday, 15'th Jun 2020The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
12:00am, Sunday, 24'th May 2020
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress
12:00am, Thursday, 21'st May 2020
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of high
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12:00pm, Wednesday, 20'th May 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agre
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12:00am, Wednesday, 20'th May 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the o
Janssen’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
12:00am, Thursday, 14'th May 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) eval
Oncternal Therapeutics, Inc. (ONCT) CEO Dr. Jim Breitmeyer on Q1 2020 Results - Earnings Call Transcript
02:09am, Sunday, 10'th May 2020
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2020 Earnings Conference Call May 7, 2020, 05:00 PM ET Company Participants Richard Vincent - CFO Jim Breitmeyer -
Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results
12:00pm, Thursday, 07'th May 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quar
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
12:00pm, Tuesday, 05'th May 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 f
The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down
11:29am, Wednesday, 25'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord
Is Oncternal Therapeutics (NASDAQ:ONCT) In A Good Position To Invest In Growth?
12:36pm, Wednesday, 18'th Mar 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
